CA2377254C - Non-malignant disease treatment with ras antagonists - Google Patents

Non-malignant disease treatment with ras antagonists Download PDF

Info

Publication number
CA2377254C
CA2377254C CA002377254A CA2377254A CA2377254C CA 2377254 C CA2377254 C CA 2377254C CA 002377254 A CA002377254 A CA 002377254A CA 2377254 A CA2377254 A CA 2377254A CA 2377254 C CA2377254 C CA 2377254C
Authority
CA
Canada
Prior art keywords
fts
ras
cells
mice
treated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002377254A
Other languages
English (en)
French (fr)
Other versions
CA2377254A1 (en
Inventor
Yoel Kloog
Michael Brownstein
Joab Chapman
Rafael Bruck
Shimon Reif
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of CA2377254A1 publication Critical patent/CA2377254A1/en
Application granted granted Critical
Publication of CA2377254C publication Critical patent/CA2377254C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
CA002377254A 1999-06-18 2000-06-19 Non-malignant disease treatment with ras antagonists Expired - Fee Related CA2377254C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14019299P 1999-06-18 1999-06-18
US60/140,192 1999-06-18
PCT/US2000/016863 WO2000078303A1 (en) 1999-06-18 2000-06-19 Non-malignant disease treatment with ras antagonists

Publications (2)

Publication Number Publication Date
CA2377254A1 CA2377254A1 (en) 2000-12-28
CA2377254C true CA2377254C (en) 2009-08-18

Family

ID=22490144

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002377254A Expired - Fee Related CA2377254C (en) 1999-06-18 2000-06-19 Non-malignant disease treatment with ras antagonists

Country Status (6)

Country Link
US (1) US6462086B1 (https=)
EP (1) EP1187605A4 (https=)
JP (1) JP2003502365A (https=)
AU (1) AU5497000A (https=)
CA (1) CA2377254C (https=)
WO (1) WO2000078303A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1483283A4 (en) 2002-03-13 2007-04-11 Signum Biosciences Inc MODULATION OF PROTEIN METHYLATION AND PHOSPHOPROTEIN PHOSPHATE
WO2004103352A1 (en) * 2003-05-23 2004-12-02 Ramot At Tel Aviv University, Ltd. Ras antagonists for treating neurodegenerative disorders
CA2535944A1 (en) * 2003-08-22 2005-03-03 University Of Virginia Patent Foundation Blockade of mtor to prevent a hormonal adaptive response
US20050216049A1 (en) * 2004-03-29 2005-09-29 Jones Donald K Vascular occlusive device with elastomeric bioresorbable coating
US7416757B2 (en) * 2004-04-08 2008-08-26 Cordis Neurovascular, Inc. Method of making active embolic coil
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
EP2301528B1 (en) * 2004-08-18 2013-04-03 Kadmon Corporation, LLC Use of FTS for treating malignant disorders
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
CA2601777A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
WO2007064448A2 (en) * 2005-11-28 2007-06-07 Ramot At Tel Aviv University, Ltd. Cancer treatment using fts and 2-deoxyglucose
WO2007116396A1 (en) * 2006-04-11 2007-10-18 Ramot At Tel Aviv University Ltd. Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor
WO2008126094A1 (en) * 2007-04-17 2008-10-23 Ramot At Tel Aviv University Ltd. Treatment of myocarditis using fts
EP2523668A1 (en) * 2010-01-13 2012-11-21 Ramot at Tel-Aviv University Ltd Treatment of multiple sclerosis
WO2012104846A1 (en) * 2011-01-07 2012-08-09 Ramot At Tel-Aviv University Ltd. Ras inhibitors for treating diseases or pathological conditions characterized insulin resistance
ES2642843T3 (es) * 2011-10-07 2017-11-20 Pisces Therapeutics Llc Tratamiento de enfermedad maligna y no maligna con antagonistas de Ras
US9738614B2 (en) 2011-10-07 2017-08-22 Pisces Therapeutics, Llc Malignant and non-malignant disease treatment with Ras antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028009A1 (en) * 1993-06-01 1994-12-08 Ludwig Institute For Cancer Research Fragments of neurofibromin (nf1) and method to reverse activated ras induced malignant transformation in mammalian cells
IL107587A (en) * 1993-11-12 1998-08-16 Univ Ramot Farnesyl geranyl or geranyl-geranyl derivatives pharmaceutical compositions containing them and methods for their preparation
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
WO1998002436A1 (en) * 1996-07-15 1998-01-22 Bristol-Myers Squibb Company Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
DE19644422C2 (de) * 1996-10-25 2000-06-15 Stefan Schulz Verwendung von Terpenen zur Behandlung von Autoimmunkrankheiten und bei Transplantat-Abstoßungsreaktionen
AU9315698A (en) * 1997-09-11 1999-03-29 Beth Israel Deaconess Medical Center (rin2), a novel inhibitor of ras-mediated signaling
AU735366B2 (en) * 1997-09-29 2001-07-05 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase

Also Published As

Publication number Publication date
US6462086B1 (en) 2002-10-08
AU5497000A (en) 2001-01-09
EP1187605A4 (en) 2004-05-26
JP2003502365A (ja) 2003-01-21
CA2377254A1 (en) 2000-12-28
WO2000078303A1 (en) 2000-12-28
EP1187605A1 (en) 2002-03-20

Similar Documents

Publication Publication Date Title
CA2377254C (en) Non-malignant disease treatment with ras antagonists
Le Moigne et al. The p97 inhibitor CB-5083 is a unique disrupter of protein homeostasis in models of multiple myeloma
Gardner et al. A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo
Kim et al. Indoxyl sulfate–induced TNF‐α is regulated by crosstalk between the aryl hydrocarbon receptor, NF‐κB, and SOCS2 in human macrophages
Fitzpatrick et al. In vivo suppression of prostaglandin biosynthesis by non-steroidal anti-inflammatory agents
Wang et al. MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53
Pitchumoni et al. Pancreatitis in inflammatory bowel diseases
Lanas et al. Clinical implications of COX-1 and/or COX-2 inhibition for the distal gastrointestinal tract
Chatterjee et al. The cyclopentenone prostaglandin 15-deoxy-Δ12, 14-prostaglandin J2 ameliorates ischemic acute renal failure
Brown et al. The antioxidant glutathione protects against enteric neuron death in situ, but its depletion is protective during colitis
JP2022095882A (ja) 神経膠腫を含むがんを処置するためのエフロルニチンおよびその誘導体および類似体の組成物ならびにそれらの使用方法
Liu et al. Inhibition of (S)-armepavine from Nelumbo nucifera on autoimmune disease of MRL/MpJ-lpr/lpr mice
Fried et al. Ammonia modifies enteric neuromuscular transmission through glial γ-aminobutyric acid signaling
Van Ryn et al. Clinical experience with cyclooxygenase-2 inhibitors
Katzav et al. Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS)
Kemler et al. Inflammatory bowel disease associated circulating immune complexes
Poorvashree et al. Novel drug delivery of dual acting prodrugs of hydroxychloroquine with aryl acetic acid NSAIDs: Design, kinetics and pharmacological study
Gardner et al. A comparison of the covalent binding of clozapine, procainamide, and vesnarinone to human neutrophils in vitro and rat tissues in vitro and in vivo
US20050119237A1 (en) Non-malignant disease treatment with Ras antagonists
Yang et al. HSP90β shapes the fate of Th17 cells with the help of glycolysis‐controlled methylation modification
US6946485B2 (en) Treatment of post-angioplasty restenosis and atherosclerosis with Ras antagonists
Meyers et al. Significance of anergy to dinitrochlorobenzene (DNCB) in inflammatory bowel disease: family and postoperative studies.
Ohtani et al. In vitro and in vivo antagonistic activities of SM-31900 for the NMDA receptor glycine-binding site
Sato et al. Suppressive effect of bortezomib on LPS-induced inflammatory responses in horses
EP1664327B1 (en) METHODS OF SCREENING FOR COMPOUNDS THAT MODULATE TAFIa ACTIVITY, COMPOUNDS, AND METHODS OF USING THE COMPOUNDS

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed